Hello all,

I hope things are well in your area. I wanted to reach out to see if any have explored the use of the 'Ready to Infuse Vancomycin' premix. We were using it previously and had our informatics team build out some rules for selection of which product to dispense in response to the black box warning for risk of embryo-fetal toxicity. But we worked to phase out the use of this product in our institution as a result of risk versus benefit discussions and behaviors. We noted that there were instances where someone would grab and try to administer the premixed product that may have been meant for one patient (in order to administer on time) to another patient with plans to administer when the other dose arrives, with them not knowing the risk or difference.

What are you doing at your institution? We are reaching out because we really want to think this through, especially with the upcoming expanded dosing range of premixed product.

Look forward to your discussion!

Jameika